A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-severe Atopic Hand and Foot Dermatitis

Study Details

  1. Patients with chronic hand and foot dermatitis diagnosed at least 3 years prior to the screening visit for patients ≥18 years old, and at least 1 year prior to the screening visit for patients ≥12 to <18 years old.
  2. Patients with involvement of at least 2 anatomical areas at screening and baseline. These 2 anatomical areas could be both hands, 1 hand and 1 foot, or both feet.
  3. Patients need to have an IGA hand and foot score of 3 or 4 (moderate-to-severe disease) at screening and baseline.
Sponsor(s)
Regeneron
Principal Investigator(s)
Dr. Joseph Zahn
Contact Phone Number
Request Information
Address

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

1 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.